DOI: 10.1182/blood-2017-04-779405 ISSN:
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony Stein, Mikkael A. Sekeres, Ronan T. Swords, Bruno C. Medeiros, Christophe Willekens, Paresh Vyas, Alessandra Tosolini, Qiang Xu, Robert D. Knight, Katharine E. Yen, Sam Agresta, Stephane de Botton, Martin S. Tallman- Cell Biology
- Hematology
- Immunology
- Biochemistry
Key Points
Enasidenib, a selective inhibitor of mutant IDH2 enzymes, was safe and well tolerated in patients with IDH2-mutated myeloid malignancies. Enasidenib induced hematologic responses in patients with relapsed/refractory AML in this dose-escalation and expansion study.